Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment : Relation to Cognitive Functions and Psychopathology. / Nørbak-Emig, Henrik; Ebdrup, Bjørn H; Fagerlund, Birgitte; Svarer, Claus; Rasmussen, Hans; Friberg, Lars; Allerup, Peter N.; Rostrup, Egill; Pinborg, Lars H; Glenthøj, Birte Y.

I: International Journal of Neuropsychopharmacology, Bind 19, Nr. 5, pyw006, 05.2016, s. 1-10.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Nørbak-Emig, H, Ebdrup, BH, Fagerlund, B, Svarer, C, Rasmussen, H, Friberg, L, Allerup, PN, Rostrup, E, Pinborg, LH & Glenthøj, BY 2016, 'Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology', International Journal of Neuropsychopharmacology, bind 19, nr. 5, pyw006, s. 1-10. https://doi.org/10.1093/ijnp/pyw006

APA

Nørbak-Emig, H., Ebdrup, B. H., Fagerlund, B., Svarer, C., Rasmussen, H., Friberg, L., Allerup, P. N., Rostrup, E., Pinborg, L. H., & Glenthøj, B. Y. (2016). Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology. International Journal of Neuropsychopharmacology, 19(5), 1-10. [pyw006]. https://doi.org/10.1093/ijnp/pyw006

Vancouver

Nørbak-Emig H, Ebdrup BH, Fagerlund B, Svarer C, Rasmussen H, Friberg L o.a. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology. International Journal of Neuropsychopharmacology. 2016 maj;19(5):1-10. pyw006. https://doi.org/10.1093/ijnp/pyw006

Author

Nørbak-Emig, Henrik ; Ebdrup, Bjørn H ; Fagerlund, Birgitte ; Svarer, Claus ; Rasmussen, Hans ; Friberg, Lars ; Allerup, Peter N. ; Rostrup, Egill ; Pinborg, Lars H ; Glenthøj, Birte Y. / Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment : Relation to Cognitive Functions and Psychopathology. I: International Journal of Neuropsychopharmacology. 2016 ; Bind 19, Nr. 5. s. 1-10.

Bibtex

@article{8f10e50a1f054c1691061217d51eeafa,
title = "Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology",
abstract = "BACKGROUND: We have previously reported associations between frontal D2/3 receptor binding potential positive symptoms and cognitive deficits in antipsychotic-na{\"i}ve schizophrenia patients. Here, we examined the effect of dopamine D2/3 receptor blockade on cognition. Additionally, we explored the relation between frontal D2/3 receptor availability and treatment effect on positive symptoms.METHODS: Twenty-five antipsychotic-na{\"i}ve first-episode schizophrenia patients were examined with the Positive and Negative Syndrome Scale, tested with the cognitive test battery Cambridge Neuropsychological Test Automated Battery, scanned with single-photon emission computerized tomography using the dopamine D2/3 receptor ligand [(123)I]epidepride, and scanned with MRI. After 3 months of treatment with either risperidone (n=13) or zuclopenthixol (n=9), 22 patients were reexamined.RESULTS: Blockade of extrastriatal dopamine D2/3 receptors was correlated with decreased attentional focus (r = -0.615, P=.003) and planning time (r = -0.436, P=.048). Moreover, baseline frontal dopamine D2/3 binding potential and positive symptom reduction correlated positively (D2/3 receptor binding potential left frontal cortex rho = 0.56, P=.003; D2/3 receptor binding potential right frontal cortex rho = 0.48, P=.016).CONCLUSIONS: Our data support the hypothesis of a negative influence of D2/3 receptor blockade on specific cognitive functions in schizophrenia. This is highly clinically relevant given the well-established association between severity of cognitive disturbances and a poor functional outcome in schizophrenia. Additionally, the findings support associations between frontal D2/3 receptor binding potential at baseline and the effect of antipsychotic treatment on positive symptoms.",
author = "Henrik N{\o}rbak-Emig and Ebdrup, {Bj{\o}rn H} and Birgitte Fagerlund and Claus Svarer and Hans Rasmussen and Lars Friberg and Allerup, {Peter N.} and Egill Rostrup and Pinborg, {Lars H} and Glenth{\o}j, {Birte Y}",
note = "{\textcopyright} The Author 2016. Published by Oxford University Press on behalf of CINP.",
year = "2016",
month = may,
doi = "10.1093/ijnp/pyw006",
language = "English",
volume = "19",
pages = "1--10",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment

T2 - Relation to Cognitive Functions and Psychopathology

AU - Nørbak-Emig, Henrik

AU - Ebdrup, Bjørn H

AU - Fagerlund, Birgitte

AU - Svarer, Claus

AU - Rasmussen, Hans

AU - Friberg, Lars

AU - Allerup, Peter N.

AU - Rostrup, Egill

AU - Pinborg, Lars H

AU - Glenthøj, Birte Y

N1 - © The Author 2016. Published by Oxford University Press on behalf of CINP.

PY - 2016/5

Y1 - 2016/5

N2 - BACKGROUND: We have previously reported associations between frontal D2/3 receptor binding potential positive symptoms and cognitive deficits in antipsychotic-naïve schizophrenia patients. Here, we examined the effect of dopamine D2/3 receptor blockade on cognition. Additionally, we explored the relation between frontal D2/3 receptor availability and treatment effect on positive symptoms.METHODS: Twenty-five antipsychotic-naïve first-episode schizophrenia patients were examined with the Positive and Negative Syndrome Scale, tested with the cognitive test battery Cambridge Neuropsychological Test Automated Battery, scanned with single-photon emission computerized tomography using the dopamine D2/3 receptor ligand [(123)I]epidepride, and scanned with MRI. After 3 months of treatment with either risperidone (n=13) or zuclopenthixol (n=9), 22 patients were reexamined.RESULTS: Blockade of extrastriatal dopamine D2/3 receptors was correlated with decreased attentional focus (r = -0.615, P=.003) and planning time (r = -0.436, P=.048). Moreover, baseline frontal dopamine D2/3 binding potential and positive symptom reduction correlated positively (D2/3 receptor binding potential left frontal cortex rho = 0.56, P=.003; D2/3 receptor binding potential right frontal cortex rho = 0.48, P=.016).CONCLUSIONS: Our data support the hypothesis of a negative influence of D2/3 receptor blockade on specific cognitive functions in schizophrenia. This is highly clinically relevant given the well-established association between severity of cognitive disturbances and a poor functional outcome in schizophrenia. Additionally, the findings support associations between frontal D2/3 receptor binding potential at baseline and the effect of antipsychotic treatment on positive symptoms.

AB - BACKGROUND: We have previously reported associations between frontal D2/3 receptor binding potential positive symptoms and cognitive deficits in antipsychotic-naïve schizophrenia patients. Here, we examined the effect of dopamine D2/3 receptor blockade on cognition. Additionally, we explored the relation between frontal D2/3 receptor availability and treatment effect on positive symptoms.METHODS: Twenty-five antipsychotic-naïve first-episode schizophrenia patients were examined with the Positive and Negative Syndrome Scale, tested with the cognitive test battery Cambridge Neuropsychological Test Automated Battery, scanned with single-photon emission computerized tomography using the dopamine D2/3 receptor ligand [(123)I]epidepride, and scanned with MRI. After 3 months of treatment with either risperidone (n=13) or zuclopenthixol (n=9), 22 patients were reexamined.RESULTS: Blockade of extrastriatal dopamine D2/3 receptors was correlated with decreased attentional focus (r = -0.615, P=.003) and planning time (r = -0.436, P=.048). Moreover, baseline frontal dopamine D2/3 binding potential and positive symptom reduction correlated positively (D2/3 receptor binding potential left frontal cortex rho = 0.56, P=.003; D2/3 receptor binding potential right frontal cortex rho = 0.48, P=.016).CONCLUSIONS: Our data support the hypothesis of a negative influence of D2/3 receptor blockade on specific cognitive functions in schizophrenia. This is highly clinically relevant given the well-established association between severity of cognitive disturbances and a poor functional outcome in schizophrenia. Additionally, the findings support associations between frontal D2/3 receptor binding potential at baseline and the effect of antipsychotic treatment on positive symptoms.

U2 - 10.1093/ijnp/pyw006

DO - 10.1093/ijnp/pyw006

M3 - Journal article

C2 - 26819282

VL - 19

SP - 1

EP - 10

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 5

M1 - pyw006

ER -

ID: 162291024